Evaluation of Hepatitis A and B Vaccine Antibody Response in Pediatric Patients with Type 1 Diabetes Mellitus
Abstract views: 175
/ 
PDF downloads: 81
DOI:
https://doi.org/10.5281/zenodo.7601047Keywords:
Anti-HBS, Anti-HAV IgG, Pediatric, Type 1 Diabetes MellitusAbstract
Aim: Type 1 Diabetes; in addition to blood glucose dysregulation, it also progresses with secondary immune dysregulation. Hepatitis A and hepatitis B viruses can therefore cause severe infection in children with type 1 diabetes.
Material and Methods: In this cross-sectional study, pediatric patients with type 1 diabetes mellitus (T1D), aged 3-18, with completed vaccination schedules were involved. Hepatitis B (hepB) vaccine protection was evaluated by measuring anti hepatitis B surface antigen (anti-HBS), and hepatit A (hepA) immunity is measured by anti-hepatitis A virus immunoglobulin G (Anti-HAV IgG) level.
Results: Three hundred and forty-five patients and 250 controls, totally 595 cases were included. The age of diabetic cases was 12.7±4.0 years and the age of control group was 11.9±4.7 years (p=0.027). While anti-HBS positivity was 51.3% (177 patients) in T1D children, it was higher with 59.4% (149 patients) in the control group (p=0.047). The number of participants who received HepA vaccine was 230 (38.6%). Anti-HAV IgG positivity was similar in T1D and control groups (173 (50.2%) and 136 (54.4%), respectively, p=0.378). Anti-HAV IgG positivity was 29.4% (n:107) in 365 participants who were not vaccinated against hepA, while this rate was 90.8% (n:209) in 230 children who were vaccinated (p<0.001).
Conclusion: In T1D patient group, while adequate immune response was achieved against hepA virus after vaccination, insufficient immune response was observed against hepB virus despite vaccination. Anti-HAV IgG testing in this risky group of chronic patients who have not been vaccinated with hepA vaccine at the time of diagnosis may be taken into account. In all patients, regardless of vaccination status, we recommend routine monitoring of anti-HBS levels, this screening should be included in the guidelines, and a booster dose of vaccine for patients with inadequate antibody response should be applied.
References
Altındiş, M. (2012). Hepatit A Enfeksiyonlarına Güncel Yaklaşım. Viral Hepatit Dergisi, 18(3), 81-86. https://doi.org/10.4274/Vhd.35744
Alkan Çevi̇ker, S., Günal, Ö., & Kiliç, S. S. (2019). Analysis of Adult Acute Viral Hepatitis A Cases. Flora the Journal of Infectious Diseases and Clinical Microbiology, 24(4), 329-335. https://doi.org/10.5578/flora.68372
Arslanoğlu, İ., Çetin, B., İşgüven, P., & Karavuş, M. (2002). Anti-HB Response to Standard Hepatitis Β Vaccination in Children and Adolescents with Diabetes Mellitus. Journal of Pediatric Endocrinology and Metabolism, 15(4). https://doi.org/10.1515/JPEM.2002.15.4.389
Bond, W. (1981). Survival of hepatitis B virus after drying and storage for one week. The Lancet, 317(8219), 550-551. https://doi.org/10.1016/S0140-6736(81)92877-4
Chang, Y.-C., Wang, J.-H., Chen, Y.-S., Lin, J.-S., Cheng, C.-F., & Chu, C.-H. (2014). Hepatitis B virus vaccination booster does not provide additional protection in adolescents: A cross-sectional school-Craig, M. E., Codner, E., Mahmud, F. H., Marcovecchio, M. L., DiMeglio, L. A., Priyambada, L., & Wolfsdorf, J. I. (2022). ISPAD Clinical Practice Consensus Guidelines 2022: Editorial. Pediatric Diabetes, 23(8), 1157–1159. https://doi.org/10.1111/pedi.13441
Elrashidy, H., Elbahrawy, A., El-Didamony, G., Mostafa, M., George, N. M., Elwassief, A., … Abdelbasseer, M. A. (2013). Antibody levels against hepatitis B virus after hepatitis B vaccination in Egyptian diabetic children and adolescents. Human Vaccines & Immunotherapeutics, 9(9), 2002-2006. https://doi.org/10.4161/hv.25426
Fiçicioǧlu, C., Mikla, S., Midilli, K., Aydin, A., Çam, H., & Erǧin, S. (1995). Reduced immune response to hepatitis B vaccine in children with insulin dependent diabetes. Pediatrics International, 37(6), 687-690. https://doi.org/10.1111/j.1442-200X.1995.tb03404.x
Halota, W., Muszyńska, M., & Pawłowska, M. (2002). Hepatitis B virus serologic markers and anti-hepatitis B vaccination in patients with diabetes. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 8(7), CR516-519.
Leonardi, S., Vitaliti, G., Garozzo, M. T., Miraglia del Giudice, M., Marseglia, G., & La Rosa, M. (2012). Hepatitis B vaccination failure in children with diabetes mellitus? The debate continues. Human Vaccines & Immunotherapeutics, 8(4), 448-452. https://doi.org/10.4161/hv.19107
Lu, C., Ni, Y., Chiang, B., Chen, P., Chang, M., Chang, L., … Lee, C. (2008). Humoral and Cellular Immune Responses to a Hepatitis B Vaccine Booster 15–18 Years after Neonatal Immunization. The Journal of Infectious Diseases, 197(10), 1419-1426. https://doi.org/10.1086/587695
Lu, C.-Y., Chiang, B.-L., Chi, W.-K., Chang, M.-H., Ni, Y.-H., Hsu, H.-M., … Lee, C.-Y. (2004). Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology, 40(6), 1415-1420. https://doi.org/10.1002/hep.20490
Martinetti, M., De Silvestri, A., Belloni, C., Pasi, A., Tinelli, C., Pistorio, A., … Cuccia, M. (2000). Humoral response to recombinant hepatitis B virus vaccine at birth: Role of HLA and beyond. Clinical Immunology (Orlando, Fla.), 97(3), 234-240. https://doi.org/10.1006/clim.2000.4933
Mayer-Davis, E. J., Kahkoska, A. R., Jefferies, C., Dabelea, D., Balde, N., Gong, C. X., … Craig, M. E. (2018). ISPAD Clinical Practice Consensus Guidelines 2018: Definition, epidemiology, and classification of diabetes in children and adolescents. Pediatric Diabetes, 19, 7-19. https://doi.org/10.1111/pedi.12773
Büyüki̇nan, M., & Kilinç, M. Y. (2021). Tip 1 diyabetes mellitus tanili çocuklarda hepatit A ve B seroprevalansı. Kocatepe Tıp Dergisi, 22(1), 57–63. https://doi.org/10.18229/kocatepetip.592207
Mikk, M., Pfeiffer, S., Kiviniemi, M., Laine, A., Lempainen, J., Härkönen, T., … The Finnish Pediatric Diabetes Register. (2020). HLA‐DR‐DQ haplotypes and specificity of the initial autoantibody in islet specific autoimmunity. Pediatric Diabetes, 21(7), 1218-1226. https://doi.org/10.1111/pedi.13073
Onal, Z., Ersen, A., Bayramoglu, E., Yaroglu Kazancı, S., Onal, H., & Adal, E. (2016). Seroprotection status of hepatitis B and measles vaccines in children with type 1 diabetes mellitus. Journal of Pediatric Endocrinology and Metabolism, 29(9). https://doi.org/10.1515/jpem-2015-0211
Roznovsky, L., Orsagova, I., Kloudova, A., Tvrdik, J., Kabieszova, L., Lochman, I., … Pliskova, L. (2010). Long-term protection against hepatitis B after newborn vaccination: 20-year follow-up. Infection, 38(5), 395-400. https://doi.org/10.1007/s15010-010-0039-7
Schaffzin, J. K., Southwick, K. L., Clement, E. J., Konings, F., Ganova-Raeva, L., Xia, G., … Johnson, G. S. (2012). Transmission of hepatitis B virus associated with assisted monitoring of blood glucose at an assisted living facility in New York State. American Journal of Infection Control, 40(8), 726-731. https://doi.org/10.1016/j.ajic.2011.11.002
Schillie, S., Vellozzi, C., Reingold, A., Harris, A., Haber, P., Ward, J. W., & Nelson, N. P. (2018). Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR. Recommendations and Reports, 67(1), 1-31. https://doi.org/10.15585/mmwr.rr6701a1
Sevda ARSLAN & Seltap GÜLCÜ. (2018, 1): 34-43). Çocuklarda Aşı Uygulamaları: Güncel Bir Gözden Geçirme.
Silvestri, F., Tromba, V., Mazzotta, I., & Costantino, F. (2019). How diabetes type 1 affects immune response to hepatitis B virus vaccine in pediatric population? Evaluation of a booster dose in unresponsive subjects with type 1 diabetes. Minerva Pediatrics. https://doi.org/10.23736/S0026-4946.19.05678-0
Wang, C., Tang, J., Song, W., Lobashevsky, E., Wilson, C. M., & Kaslow, R. A. (2004). HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology (Baltimore, Md.), 39(4), 978-988. https://doi.org/10.1002/hep.20142
Zhou, Z., & Jensen, P. E. (2013). Structural Characteristics of HLA-DQ that May Impact DM Editing and Susceptibility to Type-1 Diabetes. Frontiers in Immunology, 4. https://doi.org/10.3389/fimmu.2013.00262
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 GEVHER NESIBE JOURNAL OF MEDICAL AND HEALTH SCIENCES
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The journal is licensed under a 